Studies have shown that the p38MAPK inhibitor sb239063 can effectively reduce the expression level of IL-1β after II/R by inhibiting the p38MAPK pathway, significantly improving lung injury, and providing a new therapeutic approach for the clinical application of p38MAPK as an intervention against ALI after II/R [15]. This evidence concerns the gene IL1B and acute respiratory distress syndrome.